Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Geriatrics Research(Electronic Edition) ›› 2024, Vol. 11 ›› Issue (04): 38-45. doi: 10.3760/cma.j.issn.2095-8757.2024.04.007

• Reviews • Previous Articles    

Disrupter of telomeric silencing 1-like in bone-related diseases

Ying Zhu1, Hanbing Li1, Yanpan Gao2,()   

  1. 1. College of Pharmacy,Zhejiang University of Technology,Hangzhou 310014,China
    2. Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province,School of Medicine,Hangzhou City University,Hangzhou 310015,China
  • Received:2024-09-27 Online:2024-11-28 Published:2025-03-14
  • Contact: Yanpan Gao

Abstract:

In recent years, more and more studies have shown that epigenetic regulatory factors play an important role in bone development and bone diseases.Among them, the regulation of histone methylation level is one of the hot topics.Disrupter of telomeric silencing 1-like (DOT1L) is the only enzyme known to catalyze the methylation of histone H3K79.Recently, the role of DOT1L in bone metabolism and related diseases has received much attention.The abnormal expression of DOT1L often causes a series of bone diseases, such as osteoarthritis, osteoporosis and skeletal developmental disorders,which indicates that DOT1L plays an important role in maintaining bone development and functional homeostasis.In addition, there is also preliminary evidence for a potential role of DOT1L in bone tumorigenesis.In terms of mechanism, the pathogenesis of osteoarthritis is closely related to DOT1Lregulated Sirt1/Wnt pathway; the pathogenesis of osteoporosis is closely related to the regulation of oxidative environment and mir181-mediated KAT2B degradation by DOT1L.This article reviews the role of DOT1L in bone development and bone diseases, which provides a new target and treatment strategy for the treatment of bone diseases.

Key words: Disrupter of telomeric silencing 1-like, Bone development, Bone diseases, Osteoarthritis, Osteoporosis, Bone tumor

京ICP 备07035254号-15
Copyright © Chinese Journal of Geriatrics Research(Electronic Edition), All Rights Reserved.
Tel: 0571-81595383 E-mail: zhlnbyj@126.com
Powered by Beijing Magtech Co. Ltd